Department of Anesthesiology, Operative Intensive Care Medicine and Pain Therapy, University Hospital, Justus-Liebig-University, 35392 Giessen, Germany.
Int J Mol Sci. 2024 Feb 16;25(4):2342. doi: 10.3390/ijms25042342.
The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the coagulation system is not fully understood. SARS-CoV-2 penetrates cells through angiotensin-converting enzyme 2 (ACE2) receptors, leading to its downregulation. Des-arginine-bradykinin (DA9B) is degraded by ACE2 and causes vasodilation and increased vascular permeability. Furthermore, DA9B is associated with impaired platelet function. Therefore, the aim of this study was to evaluate the effects of DA9B on platelet function and coagulopathy in critically ill coronavirus disease 2019 (COVID-19) patients. In total, 29 polymerase-positive SARS-CoV-2 patients admitted to the intensive care unit of the University Hospital of Giessen and 29 healthy controls were included. Blood samples were taken, and platelet impedance aggregometry and rotational thromboelastometry were performed. Enzyme-linked immunosorbent assays measured the concentrations of DA9B, bradykinin, and angiotensin 2. Significantly increased concentrations of DA9B and angiotensin 2 were found in the COVID-19 patients. A negative effect of DA9B on platelet function and intrinsic coagulation was also found. A sub-analysis of moderate and severe acute respiratory distress syndrome patients revealed a negative association between DA9B and platelet counts and fibrinogen levels. DA9B provokes inhibitory effects on the intrinsic coagulation system in COVID-19 patients. This negative feedback seems reasonable as bradykinin, which is transformed to DA9B, is released after contact activation. Nevertheless, further studies are needed to confirm our findings.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)对凝血系统的影响尚未完全了解。SARS-CoV-2 通过血管紧张素转换酶 2(ACE2)受体进入细胞,导致其下调。去精氨酸缓激肽(DA9B)被 ACE2 降解,引起血管扩张和血管通透性增加。此外,DA9B 与血小板功能障碍有关。因此,本研究旨在评估 DA9B 对重症 2019 冠状病毒病(COVID-19)患者血小板功能和凝血障碍的影响。共纳入 29 名聚合酶阳性 SARS-CoV-2 患者和 29 名健康对照者,他们均入住吉森大学医院的重症监护病房。采集血样,进行血小板阻抗聚集和旋转血栓弹性测定。酶联免疫吸附测定法测量 DA9B、缓激肽和血管紧张素 2 的浓度。COVID-19 患者中发现 DA9B 和血管紧张素 2 的浓度显著升高。还发现 DA9B 对血小板功能和内在凝血有负面影响。对中度和重度急性呼吸窘迫综合征患者的亚分析显示,DA9B 与血小板计数和纤维蛋白原水平呈负相关。DA9B 对 COVID-19 患者的内在凝血系统产生抑制作用。这种负反馈似乎是合理的,因为缓激肽被转化为 DA9B 后,在接触激活后被释放。然而,需要进一步的研究来证实我们的发现。